Close Menu

stock rating

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investment firm Mizuho Securities has initiated coverage of Complete Genomics with an Outperform rating and a 12-month price target of $10.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – William Blair initiated coverage of Sequenom today with an Outperform rating, citing the commercial potential of the San Diego-based company's T21 molecular diagnostics test.

While a number of analysts maintained prior ratings on Exact Sciences, Rodman & Renshaw downgraded the company to Perform from Outperform.

The analyst said that the launch of GTG's BrevaGen test in the US in June is expected to "add significantly to revenues from FY 13 and profit in FY 14."

Several analysts lowered EPS, revenue, and price target estimates for Life Tech, though one analyst cited a bright note on the company's Ion Torrent business.

Analyst Amit Bhalla said that trade-in revenue from customers who purchase the HiSeq 2000 platform would not be a "significant contributor," and trimmed total revenue estimates for the second quarter and full-year 2011.

The bank cited a lack of apparent competitive bids to acquire Gen-Probe in dropping its price target to $75.

Pages

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.